News Sentiment

NEUP sentiment intelligence

Neuphoria Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.54 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+4.7% over one week, -19.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Number of shareholders of Neuphoria Therapeutics Inc. – NASDAQ:NEUP

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction 4.7% Price confirming higher
Trend fit Trend inactive -19.0% over four weeks
Fair value -40.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 28
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 8
TradingKey 6
simplywall.st 3
Finviz 2
Investing.com 2
Moomoo 2
Stocktwits 1

Event Lens

What the news is about

Classified themes
Earnings 15
Market update 15
Deals and strategy 8
Analyst action 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-43 of 43
TradingView Direct company coverage

Neuphoria Therapeutics Inc expected to post a loss of $1.12 a share - Earnings Preview

Neuphoria Therapeutics Inc. is projected to report an earnings loss of $1.12 per share. This information comes from an earnings preview provided by Refinitiv. The article provides no additional details beyond this forecasted loss.

Tone
Negative 32/100
Event
Earnings
Published
15 May 2026 20:10
Source
TradingView
Zacks Investment Research Direct company coverage

Neuphoria Therapeutics Inc. (NEUP)

Tone
Neutral 50/100
Event
Market update
Published
26 Dec 2024 20:11
Source
Zacks Investment Research